In a preclinical study, Cedars-Sinai investigators found that boosting angiotensin-converting enzyme (ACE) in key immune cells called microglia in the brain helped protect the brains of specially bred laboratory mice against Alzheimer’s disease. Their …
It often starts with restless sleep. Mobility, swallowing, and speaking disorders are also typical. Yet a range of other symptoms make it difficult to diagnose anti-IgLON5 disease. Left untreated, this rare autoimmune disease leads to severe disabiliti…
New research from The University of Toledo suggests that individuals with anemia may have a significantly higher risk of developing severe complications if they contract malaria. The findings were published this month in the peer-reviewed journal Infec…
Killer immune cells destroy cancer cells and cells infected by virus. These CD8+ T cells are activated after detection of viral infection or growth of “non-self” tumor cells. However, in chronic viral infection and cancer, the killer cells often lapse …
A joint research team led by Professor Eijiro Miyako of the Japan Advanced Institute of Science and Technology (JAIST), in collaboration with Daiichi Sankyo Co., Ltd. and University of Tsukuba, has developed an immune-independent bacterial cancer thera…
At the time when patients with lupus, or systemic lupus erythematosus (SLE), are diagnosed, approximately 15% to 30% will already have the inflammation-caused kidney disease lupus nephritis, which compromises kidney function and can lead to kidney fail…
When the COVID pandemic hit, many people turned to the eerily prescient film “Contagion” (2011) for answers—or at least for catharsis. Suddenly, its hypothetical plot felt all too real. Applauded for its scientific accuracy, the film offered more than …
Scientists at the National Institute of Biological Sciences, Beijing report that two pore-forming proteins from the common mold Alternaria alternata puncture airway epithelial membranes and initiate signals that drive allergic airway inflammation.
New research has uncovered a novel mechanism that may help explain why some people with cancer respond remarkably well to immunotherapy while others don’t.
The U.S. Food and Drug Administration has approved Apellis Pharmaceuticals’ Empaveli (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).
